CN112292128A - Ep4抑制剂和其用途 - Google Patents

Ep4抑制剂和其用途 Download PDF

Info

Publication number
CN112292128A
CN112292128A CN201980033839.6A CN201980033839A CN112292128A CN 112292128 A CN112292128 A CN 112292128A CN 201980033839 A CN201980033839 A CN 201980033839A CN 112292128 A CN112292128 A CN 112292128A
Authority
CN
China
Prior art keywords
alkyl
group
carbon atoms
radical
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980033839.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·曼弗雷迪
J·埃切迪
长久厚
武之令
奥村貴子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ascat Ltd
Ares Medical Ltd
Original Assignee
Ascat Ltd
Ares Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascat Ltd, Ares Medical Ltd filed Critical Ascat Ltd
Publication of CN112292128A publication Critical patent/CN112292128A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980033839.6A 2018-04-16 2019-04-16 Ep4抑制剂和其用途 Pending CN112292128A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862658494P 2018-04-16 2018-04-16
US62/658,494 2018-04-16
US201862737219P 2018-09-27 2018-09-27
US62/737,219 2018-09-27
PCT/US2019/027603 WO2019204257A1 (en) 2018-04-16 2019-04-16 Ep4 inhibitors and use thereof

Publications (1)

Publication Number Publication Date
CN112292128A true CN112292128A (zh) 2021-01-29

Family

ID=66589884

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980033839.6A Pending CN112292128A (zh) 2018-04-16 2019-04-16 Ep4抑制剂和其用途

Country Status (7)

Country Link
US (3) US10973834B2 (enExample)
EP (1) EP3781162A1 (enExample)
JP (2) JP2021522211A (enExample)
CN (1) CN112292128A (enExample)
AU (1) AU2019255196A1 (enExample)
CA (1) CA3096546A1 (enExample)
WO (1) WO2019204257A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112292128A (zh) 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 Ep4抑制剂和其用途
US20210315909A1 (en) 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
LT3860998T (lt) 2018-10-05 2024-06-25 Annapurna Bio Inc. Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu
EP3722319A1 (en) * 2019-04-09 2020-10-14 Rottapharm Biotech S.r.l. Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours
CN110386941A (zh) * 2019-08-15 2019-10-29 上海邦耀生物科技有限公司 Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗
WO2021205367A1 (en) * 2020-04-08 2021-10-14 Askat Inc. Use of ep4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia
WO2021226162A1 (en) * 2020-05-05 2021-11-11 Arrys Therapeutics, Inc. Ep4 antagonists and their use in the treatment of proliferative diseases
WO2022020114A2 (en) 2020-07-10 2022-01-27 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
EP4215214A4 (en) * 2020-09-16 2024-07-03 Osaka University THERAPEUTIC AGENT AGAINST CANCER, IMMUNOSTIMULANT AND SCREENING METHOD FOR ANTI-CANCER SUBSTANCE
CN114907267A (zh) * 2021-02-08 2022-08-16 中国科学院上海药物研究所 用于抗肿瘤的药物组合

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120088723A1 (en) * 2009-04-22 2012-04-12 Raqualia Pharma Inc. Selective ep4 receptor agonistic substance for treatment of cancer
US20150004175A1 (en) * 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
CN106572993A (zh) * 2014-05-23 2017-04-19 卫材R&D管理有限公司 用于治疗癌症的组合疗法
WO2018008711A1 (ja) * 2016-07-07 2018-01-11 小野薬品工業株式会社 Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
CA2536870C (en) 2003-09-03 2009-10-27 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
AU2006221699A1 (en) 2005-03-11 2006-09-14 Pfizer Inc. Crystal forms of an imidazole derivative
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
EP2296789A1 (fr) 2008-05-29 2011-03-23 Saint-Gobain Centre de Recherches et d'Etudes Européen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
JP5594754B2 (ja) 2009-07-13 2014-09-24 国立大学法人 東京大学 運行実績を活用したオンデマンドバスの運行スケジューリングシステム及びその方法
IN2015DN02826A (enExample) 2009-09-03 2015-09-11 Merck Sharp & Dohme
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
CA2789665C (en) 2010-02-22 2020-06-16 Askat Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
NO2694640T3 (enExample) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US10391086B2 (en) 2013-03-19 2019-08-27 Askat Inc. Use of EP4 receptor antagonists in the treatment of cartilage disease
KR20150130404A (ko) 2013-03-19 2015-11-23 에스크엣 인크. 연골질환 치료에서의 ep4 수용체 길항제의 용도
CA2997692A1 (en) 2014-03-06 2015-09-11 Aratana Therapeutics, Inc. Crystalline forms of grapiprant
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
US20190365680A1 (en) 2016-11-04 2019-12-05 Askat Inc. Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
CN112292128A (zh) * 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 Ep4抑制剂和其用途
US20210315909A1 (en) 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
IL280051B2 (en) 2018-07-11 2024-03-01 Arrys Therapeutics Inc EP4 inhibitors and their synthesis
CA3113468A1 (en) 2018-09-27 2020-04-02 Arrys Therapeutics, Inc. Grapiprant unit dosage forms
WO2021205367A1 (en) * 2020-04-08 2021-10-14 Askat Inc. Use of ep4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120088723A1 (en) * 2009-04-22 2012-04-12 Raqualia Pharma Inc. Selective ep4 receptor agonistic substance for treatment of cancer
US8921391B2 (en) * 2009-04-22 2014-12-30 Raqualia Pharma Inc. Selective EP4 receptor antagonistic substance for treatment of cancer
US20150004175A1 (en) * 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
CN106572993A (zh) * 2014-05-23 2017-04-19 卫材R&D管理有限公司 用于治疗癌症的组合疗法
WO2018008711A1 (ja) * 2016-07-07 2018-01-11 小野薬品工業株式会社 Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MOUSUMI MAJUMDER: "EP4 as a Therapeutic Target for Aggressive Human Breast Cancer", vol. 19, pages 1 - 20 *
XINGFENG BAO: "Combination of EP4 antagonist and checkpoint inhibitors promotes anti-tumor effector T cells in preclinical tumor models", vol. 3, no. 2, pages 1, XP021235516, DOI: 10.1186/2051-1426-3-S2-P350 *
叶定伟: "《膀胱肿瘤家庭防治手册》", 31 December 2016, 同济大学出版社, pages: 88 - 89 *
廖子君，宋张骏，姚俊涛主编: "《最新简明肿瘤临床实践指南》", 30 April 2017, 陕西科学技术出版社, pages: 177 - 179 *

Also Published As

Publication number Publication date
WO2019204257A1 (en) 2019-10-24
JP2021522211A (ja) 2021-08-30
US20210290641A1 (en) 2021-09-23
CA3096546A1 (en) 2019-10-24
US20190314390A1 (en) 2019-10-17
US10973834B2 (en) 2021-04-13
AU2019255196A1 (en) 2020-11-12
US20240066040A1 (en) 2024-02-29
JP2023165946A (ja) 2023-11-17
EP3781162A1 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
US20240066040A1 (en) Ep4 inhibitors and use thereof
US20240254120A1 (en) Ep4 inhibitors and synthesis thereof
KR20220030222A (ko) Tead 억제제 및 이의 용도
CN113271945A (zh) 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
US12295962B2 (en) Polymorphic compounds and uses thereof
CN115916199A (zh) 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
CN110812478A (zh) 免疫疗法与mdm2抑制剂的组合
CN108778332B (zh) Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
CN114224889A (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
US12459895B2 (en) MEK inhibitors and uses thereof
CA3196535A1 (en) Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
JP2022500485A (ja) グラピプラント単位剤形
EP4316492B1 (en) Combination of a multikinase inhibitor with a pd-1/pd-l1 antibody and uses thereof
CN114206869A (zh) Cxcr4抑制剂和其用途
CN114533879B (zh) 治疗癌症的联合疗法
WO2026097102A1 (en) Methods for the treatment of cancer using microtubule targeting agents in combination with immune checkpoint modulators
TW202116318A (zh) Ｈｓｐ９０結合共軛物及其組合療法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210129

WD01 Invention patent application deemed withdrawn after publication